[ad_1]
Polyneuron Pharmaceuticals AG develops glycopolymers that mimic autoantibody epitopes that attack the nervous system, offering a new strategy to specifically prevent symptoms of autoimmune disease without reducing the rest of the immune system. The company said it would use Series A funding revenues to conduct the company's lead candidate, PN-1007, the Phase Ia trial, which targets anti-MAG neuropathy, an orphan nervous system disease. . In addition, the company will continue the preclinical development of three injectable glycopolymer candidates identified by its Antibody-Catch ™ platform.
When financing, Polyneuron added Graziano Seghezzi (Sofinnova Partners) and David Mott (NEA) to its board of directors.
Polyneuron was created as the Department of Pharmaceutical Sciences of the University of Basel, created in 2014 by Dr. Ruben Herrendorff (CEO), Dr. Pascal Hänggi (CSO), Professor Beat Ernst, Drug Discovery Expert based on carbohydrates, and neurologist Prof. Dr. med. Andreas J. Steck, an expert on autoimmune disorders of the nervous system. The company is supported by the BaseLaunch Accelerator initiative.
PN-1007 was designed to target the IgM autoantibodies responsible for anti-MAG neuropathy, a chronic disabling disease of the peripheral nervous system without any approved treatment. The PN-1007 mimics the natural epitope of HNK-1 carbohydrates and binds to the circulating antibodies that cause the disease. By eliminating these pathogenic antibodies, PN-1007 could protect the integrity of the neuronal myelin sheaths of anti-MAG patients.
Polyneuron is currently focusing on autoimmune diseases involving autoantibodies to carbohydrate epitopes.
Source link
